Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 17 January 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Infliximab in steroid dependent Crohn's patients treated with azathioprine or mercaptopurine

Infliximab may be used while waiting for the effect of azathioprine or 6-mercaptopurine in steroid-dependent patients, reported researchers at DDW 2003.

News image

fiogf49gjkf04

In this study, researchers from France assessed whether infliximab, combined with azathioprine (AZA) or 6-mercaptopurine (6MP), could achieve clinical remission without steroids in steroid-dependent Crohn's disease (CD) patients.

Dr Marc Lemann and colleagues selected CD patients with active disease, despite treatment with prednisone (≥10 mg/d) for more than 6 months, for inclusion in the trial.

The research team treated all patients with either AZA (2 to 3 mg/kg/d) or 6MP (1 to 1.5 mg/kg/d).

Patients were divided into 2 strata:

  • Patients who received AZA or 6MP at a stable dose for at least 6 months and still had active disease (CDAI >150) at inclusion (AZA failure).
  • Patients not yet treated with AZA/6MP (naive).

There were 22 centers participating to the trial. From these centers 115 patients (63 female, mean age 30 years) were randomized, 56 to the AZA failure stratum and 59 to the naive stratum.

75% of patients in the infliximab group were in remission at week 12.
American Gastroenterological Association

Within each stratum, the team then randomized patients to receive either 3 infusions of infliximab (5 mg/kg) at day 0, week 2 and week 6, or 3 infusions of placebo.

During the 24 weeks of the study, if a clinical remission was achieved (CDAI <150), then the team tapered the steroids using a standardized scheme. In those patients who experienced a relapse, the team increased the dose of steroids until a new remission was achieved, and then they were tapered again.

The researchers set the primary end-point as remission off steroids at week 24.

The secondary end-points were remission without steroids at week 12, treatment failure due to steroid resistance, and a side-effect steroid score.

Of the 115 patients, 36% had Crohn's disease located in the colon, 14% in the small bowel, and 50% in both. The team found active perianal lesions were present in 22%.

At inclusion, patients had a mean CDAI of 189. The team determined that the median duration of steroid treatment was 15 months, and median dose of prednisone was 30 mg/d.

In stratum 1, median duration of AZA/6MP treatment was 24 months.

Overall, 57 patients were allocated to infliximab and 58 to placebo infusions.

The team found that 75% of patients in the infliximab group were in remission off steroids at week 12, compared with 38% in the placebo group. At week 24, 57% of the infliximab group were in remission off steroids, compared with 29% in the placebo group.

Treatment failure due to steroid resistance was less common in the infliximab group than in the placebo group (5% versus 23%, respectively).

The researchers did not identify any significant difference in infliximab efficacy between the 2 strata.

They determined that the median side-effect steroid score did not differ in the 2 groups at weeks 12 and 24.

The team identified severe adverse events in 2 patients in the infliximab group and in 4 patients in the placebo.

In their conclusion, the researchers suggested that infliximab may be used while waiting for the effect of AZA/6MP in steroid-dependent patients.

This strategy may be effective, even if AZA/6MP has previously failed, to allow steroid withdrawal.

AGA
28 May 2003

Go to top of page Email this page Email this page to a colleague

 17 January 2018 
“Weekend effect” in upper GI hemorrhage
 17 January 2018 
Gut dysbiosis and non-antibiotic prescription medications
 17 January 2018 
Reducing surgical infections in high-outlier colorectal unit
 16 January 2018 
Bundle of care in GI cancer surgery
 16 January 2018 
Anxiety about colonoscopy
 16 January 2018 
Thiopurines and colorectal neoplasia in IBD
 15 January 2018 
Risks of death after liver transplants for liver cancer
 15 January 2018 
Recent advances in hepatocellular carcinoma
 15 January 2018 
Ileostomy output using telemedicine
 12 January 2018 
Surveillance protocols after colorectal cancer resection
 12 January 2018 
Biologic therapy by pregnant women with IBD and infant vaccines
 12 January 2018 
Biologic therapies for IBD in the USA
 11 January 2018 
Genetic risk factors in GERD
 11 January 2018 
Predictor of colorectal adenoma
 11 January 2018 
Ectopic pregnancy in IBD 
 10 January 2018 
Fecal immunochemical tests for colorectal cancer screening
 10 January 2018 
Risk factors for advanced NAFLD
 10 January 2018 
Dyspepsia prevalence with gastroesophageal reflux–type symptoms
 09 January 2018 
Screening intervals for people with family histories of colorectal cancer
 09 January 2018 
Financial impact of colorectal cancer
 09 January 2018 
Current practice and future research in autoimmune hepatitis
 08 January 2018 
Improving prognosis in patients with primary sclerosing cholangitis
 08 January 2018 
Reliability of the IBD index
 08 January 2018 
Aprepitant and nausea with gastroparesis
 05 January 2018 
Autoimmune pancreatitis and IBD
 05 January 2018 
Primary nonresponse to infliximab therapy
 05 January 2018 
Anesthesia assistance in outpatient colonoscopy
 04 January 2018 
Dietary polyphenols in the etiology of IBD
 04 January 2018 
Yoga vs low-FODMAP in IBS
 04 January 2018 
Local esophageal food allergen injections in eosinophilic esophagitis
 03 January 2018 
Population health management for IBD
 03 January 2018 
GERD in asthma and COPD
 03 January 2018 
Critical research gaps in colorectal cancer
 22 December 2017 
Costs of extrahepatic manifestations of Hep C
 22 December 2017 
Cholera vaccine and risk of death in colorectal cancer
 22 December 2017 
Colonoscopy after colorectal cancer resection
 21 December 2017 
Human oral microbiome and pancreatic cancer risk
 21 December 2017 
Health management for IBD
 21 December 2017 
PPI and Alzheimer's disease
 20 December 2017 
Incidence of biopsy-verified celiac disease
 20 December 2017 
Osteoporotic fractures in Barrett's esophagus
 20 December 2017 
Management of abnormal liver blood tests
 19 December 2017 
Family burden of pediatric Crohn's in the USA
 19 December 2017 
Alcohol abstinence and alcoholic hepatitis
 19 December 2017 
Early readmission in IBD patients
 18 December 2017 
Colorectal cancer mortality with low-risk adenomas at colonoscopy
 18 December 2017 
Disease activity indices in celiac disease
 18 December 2017 
Smoking behaviour predicted the risk of surgery in Crohn's
 15 December 2017 
Molecular classification of Crohn's disease
 15 December 2017 
Medical cannabinoid legalization policy and vomiting
 15 December 2017 
Inflammatory diet pattern and colorectal cancer risk
 14 December 2017 
PPIs and gastric cancer after H.pylori eradication
 14 December 2017 
H. pylori eradication therapies in countries with clarithromycin resistance
 13 December 2017 
Disease severity in NAFLD
 13 December 2017 
Tryptophan metabolism and IBD activity
 12 December 2017 
Risk factors in undiagnosed cirrhosis
 12 December 2017 
Monitored anesthesia care for outpatient GI endoscopy
 12 December 2017 
High-risk colorectal cancer patients
 06 December 2017 
Reflux-induced chronic cough 
 06 December 2017 
Systemic inflammatory response syndrome in acute-on-chronic liver failure

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us